BigHat Biosciences
An AI and synthetic-biology platform that designs and engineers antibody therapeutics.
$75MSeries C
ParticipantCC
Catalio Capital Management
Activity from announced rounds
Activity in this selectionOct 18, 2026 · Jul 21, 2026
Catalio Capital Management is an investment manager whose official company communications identify BigHat Biosciences and Basecamp Research.
Recorded funding activity
BigHat combines AI and synthetic biology to engineer antibody therapeutics. Basecamp builds biological models from genomic data for therapeutic design, while Enveda discovers biologically active molecules from nature. The financings represent different routes from biological data to experimental medicines.
Sources
- Rounds participated in
- 6
- Confirmed lead rounds
- 2 1 roles undisclosed
- New companies
- 6 First participation on record · 0 follow-on
- Funding in participating rounds
- $696M 6 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in this selectionBasecamp Research
Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines.
$140MSeries C
ParticipantEnveda
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
$311MSeries E
LeadEvvy
Evvy combines at-home vaginal microbiome testing with clinician-reviewed results, personalized next steps and optional treatment and coaching for women’s health.
$40MSeries B
LeadSuperluminal Medicines
Superluminal Medicines combines structural biology, protein dynamics, machine learning and experimental testing to discover small-molecule drugs for difficult G protein-coupled receptor targets. Its pipeline focuses on endocrine and cardiometabolic diseases, including rare genetic and hypothalamic obesity.
$60MSeries B
ParticipantRatio Therapeutics
Developing best-in-class radiopharmaceuticals for cancer treatment
$70MSeries C
Role not disclosed